Nicotinamide phosphoribosyltransferase (NAMPT; EC 220.127.116.11), was originally discovered as the cytokine pre-B-cell colony-enhancing factor 1 (PBEF1) or visfatin, and has several suggested functions. It was found to be an important cofactor for stem cell factor– and interleukin (IL)-7-mediated B cell maturation. However, in 2002 the murine homologue of PBEF was found, and this proved to be an enzyme catalyzing the reaction between nicotinamide and 5-phosphoribosyl-1-pyrophosphate yielding nicotinamide mononucleotide (NMN), an intermediate in the biosynthesis of NAD/NADH: central molecules involved in energy metabolism, reductive biosynthesis, and antioxidation, histone deacetylation, cell death, and intracellular calcium release. This widened its potential biological activities. Interestingly, both extracellular (cytokine-like) and intracellular (enzymatic) functions seem to be responsible for its relevance in immunity, metabolism, and stress responses in both physiology and pathophysiology.
 T.B. Dahl, S. Holm , P. Aukrust, B. Halvorsen. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu. Rev. Nutr. 2012, 32, 229-243.
|Axon ID||Name||Description||From price|
|1279||FK 866||NAMPT inhibitor; NAD biosysthesis inhibitor||€90.00|
|1546||FK 866 hydrochloride||NAMPT inhibitor||€90.00|
|2602||P7C3||Proneurogenic and neuroprotective compound that activates NAMPT||€105.00|
|2253||STF 118804||Highly specific, next-generation NAMPT inhibitor||€120.00|